These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26674828)

  • 1. Improving platelet transfusion safety: biomedical and technical considerations.
    Garraud O; Cognasse F; Tissot JD; Chavarin P; Laperche S; Morel P; Lefrère JJ; Pozzetto B; Lozano M; Blumberg N; Osselaer JC
    Blood Transfus; 2016 Mar; 14(2):109-22. PubMed ID: 26674828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critical comparison of platelet preparation methods.
    Vassallo RR; Murphy S
    Curr Opin Hematol; 2006 Sep; 13(5):323-30. PubMed ID: 16888436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unresolved clinical aspects and safety hazards of blood derived- EV/MV in stored blood components: From personal memory lanes to newer perspectives on the roles of EV/MV in various biological phenomena.
    Seghatchian J; Amiral J
    Transfus Apher Sci; 2016 Aug; 55(1):10-22. PubMed ID: 27522103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research Progress of Platelet Transfusion in China.
    Wang Q; Yang J; Stevens L; Wang D
    Transfus Med Rev; 2017 Apr; 31(2):113-117. PubMed ID: 27914736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation, storage and quality control of platelet concentrates.
    Tynngård N
    Transfus Apher Sci; 2009 Oct; 41(2):97-104. PubMed ID: 19699153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet concentrates, from whole blood or collected by apheresis?
    van der Meer PF
    Transfus Apher Sci; 2013 Apr; 48(2):129-31. PubMed ID: 23535511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled platelet product using the Acrodose plus system: evaluation of feasibility, safety and efficacy.
    Sawant RB; Marathe AN
    Transfus Apher Sci; 2013 Dec; 49(3):535-8. PubMed ID: 24080148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of Platelet Concentrates for Research and Transfusion Purposes.
    Greening DW; Simpson RJ; Sparrow RL
    Methods Mol Biol; 2017; 1619():31-42. PubMed ID: 28674875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of additive solutions for platelets.
    Alhumaidan H; Sweeney J
    J Clin Apher; 2012; 27(2):93-8. PubMed ID: 22298435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collection, storage, inspection and quality control of platelet concentrates obtained by apheresis: The situation in Spain.
    Castrillo A; Jimenez-Marco T; Arroyo JL; Jurado ML; Larrea L; Maymo RM; Monge J; Muñoz C; Pajares Á; Yáñez M;
    Transfus Apher Sci; 2017 Jun; 56(3):357-361. PubMed ID: 28319015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology.
    Ostrowski SR; Bochsen L; Windeløv NA; Salado-Jimena JA; Reynaerts I; Goodrich RP; Johansson PI
    Transfusion; 2011 Feb; 51(2):344-56. PubMed ID: 20723169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of platelet concentrates derived by platelet rich plasma, buffy coat and Apheresis.
    Vasconcelos E; Figueiredo AC; Seghatchian J
    Transfus Apher Sci; 2003 Aug; 29(1):13-6. PubMed ID: 12877887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet activation of platelet concentrates derived from buffy coat and apheresis methods.
    Ali SF
    Transfus Apher Sci; 2011 Feb; 44(1):11-3. PubMed ID: 21277261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated preparation of platelet concentrates from pooled buffy coats using the Gambro OrbiSac system.
    Gulliksson H; Sjödin A; Sandgren P; Vesterinen M; Larsson S; Diedrich B
    Transfus Apher Sci; 2003 Aug; 29(1):11-2. PubMed ID: 12877886
    [No Abstract]   [Full Text] [Related]  

  • 15. Pooled platelet concentrates: an alternative to single donor apheresis platelets?
    Pietersz RN
    Transfus Apher Sci; 2009 Oct; 41(2):115-9. PubMed ID: 19716340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of random versus apheresis platelet concentrates.
    Andreu G; Vasse J; Sandid I; Tardivel R; Semana G
    Transfus Clin Biol; 2007 Dec; 14(6):514-21. PubMed ID: 18417401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High concentration plasma-reduced plateletapheresis concentrates.
    Perseghin P
    Transfus Apher Sci; 2011 Jun; 44(3):273-6. PubMed ID: 21507725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients.
    Diedrich B; Ringdén O; Watz E; Shanwell A
    Vox Sang; 2009 Oct; 97(3):254-9. PubMed ID: 19508669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?
    Schrezenmeier H; Seifried E
    Vox Sang; 2010 Jul; 99(1):1-15. PubMed ID: 20059760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets.
    Mastroianni MA; Llohn AH; Akkök ÇA; Skogheim R; Ødegaard ER; Nybruket MJ; Flesland A; Mousavi SA
    Transfus Apher Sci; 2013 Oct; 49(2):285-90. PubMed ID: 23820429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.